Literature DB >> 17712350

Modafinil: a review of neurochemical actions and effects on cognition.

Michael J Minzenberg1, Cameron S Carter.   

Abstract

Modafinil (2-[(Diphenylmethyl) sulfinyl] acetamide, Provigil) is an FDA-approved medication with wake-promoting properties. Pre-clinical studies of modafinil suggest a complex profile of neurochemical and behavioral effects, distinct from those of amphetamine. In addition, modafinil shows initial promise for a variety of off-label indications in psychiatry, including treatment-resistant depression, attention-deficit/hyperactivity disorder, and schizophrenia. Cognitive dysfunction may be a particularly important emerging treatment target for modafinil, across these and other neuropsychiatric disorders. We aimed to comprehensively review the empirical literature on neurochemical actions of modafinil, and effects on cognition in animal models, healthy adult humans, and clinical populations. We searched PubMed with the search term 'modafinil' and reviewed all English-language articles for neurochemical, neurophysiological, cognitive, or information-processing experimental measures. We additionally summarized the pharmacokinetic profile of modafinil and clinical efficacy in psychiatric patients. Modafinil exhibits robust effects on catecholamines, serotonin, glutamate, gamma amino-butyric acid, orexin, and histamine systems in the brain. Many of these effects may be secondary to catecholamine effects, with some selectivity for cortical over subcortical sites of action. In addition, modafinil (at well-tolerated doses) improves function in several cognitive domains, including working memory and episodic memory, and other processes dependent on prefrontal cortex and cognitive control. These effects are observed in rodents, healthy adults, and across several psychiatric disorders. Furthermore, modafinil appears to be well-tolerated, with a low rate of adverse events and a low liability to abuse. Modafinil has a number of neurochemical actions in the brain, which may be related to primary effects on catecholaminergic systems. These effects are in general advantageous for cognitive processes. Overall, modafinil is an excellent candidate agent for remediation of cognitive dysfunction in neuropsychiatric disorders.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17712350     DOI: 10.1038/sj.npp.1301534

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  216 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Neuropharmacology of Sleep and Wakefulness.

Authors:  Christopher J Watson; Helen A Baghdoyan; Ralph Lydic
Journal:  Sleep Med Clin       Date:  2010-12

Review 3.  The solute carrier 6 family of transporters.

Authors:  Stefan Bröer; Ulrik Gether
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  Polymorphisms of ADORA2A modulate psychomotor vigilance and the effects of caffeine on neurobehavioural performance and sleep EEG after sleep deprivation.

Authors:  S Bodenmann; C Hohoff; C Freitag; J Deckert; J V Rétey; V Bachmann; H-P Landolt
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 5.  Cognitive enhancement as a treatment for drug addictions.

Authors:  Mehmet Sofuoglu; Elise E DeVito; Andrew J Waters; Kathleen M Carroll
Journal:  Neuropharmacology       Date:  2012-06-23       Impact factor: 5.250

6.  Effects of acute modafinil on cognition in trichotillomania.

Authors:  Samuel R Chamberlain; Jon E Grant; Anna Costa; Ulrich Müller; Barbara J Sahakian
Journal:  Psychopharmacology (Berl)       Date:  2010-08-17       Impact factor: 4.530

7.  Clinical and neurocognitive changes with modafinil in obsessive-compulsive disorder: a case report.

Authors:  Winand H Dittrich; Thomas Johansen; Ashwini K Padhi; Ian E Smith; Samuel R Chamberlain; Naomi A Fineberg
Journal:  Psychopharmacology (Berl)       Date:  2010-08-06       Impact factor: 4.530

Review 8.  The treatment of cognitive impairment in schizophrenia.

Authors:  Donald C Goff; Michele Hill; Deanna Barch
Journal:  Pharmacol Biochem Behav       Date:  2010-11-27       Impact factor: 3.533

9.  In Reply: Spontaneous MAOI hypertensive reaction, not likely armodafinil - tranylcypromine interaction.

Authors:  Connor J Kinslow; Eliza C Miller
Journal:  J Neurol Sci       Date:  2019-01-08       Impact factor: 3.181

Review 10.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.